Mostrar el registro sencillo del ítem
Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF®01 or CDA/αGalCerMPEG
dc.contributor.author | López-Serrano, Sergi | |
dc.contributor.author | Cordoba, Lorena | |
dc.contributor.author | Pérez-Maillo, Mónica | |
dc.contributor.author | Pleguezuelos, Patricia | |
dc.contributor.author | Remarque, Edmond J. | |
dc.contributor.author | Ebensen, Thomas | |
dc.contributor.author | Guzmán, Carlos A. | |
dc.contributor.author | Christensen, Dennis | |
dc.contributor.author | Segalés, Joaquim | |
dc.contributor.author | Darji, Ayub | |
dc.contributor.other | Producció Animal | ca |
dc.date.accessioned | 2022-01-25T11:00:38Z | |
dc.date.available | 2022-01-25T11:00:38Z | |
dc.date.issued | 2021-07-06 | |
dc.identifier.citation | López-Serrano, Sergi, Lorena Cordoba, Mónica Pérez-Maillo, Patricia Pleguezuelos, Edmond J. Remarque, Thomas Ebensen, Carlos A. Guzmán, Dennis Christensen, Joaquim Segalés, and Ayub Darji. 2021. "Immune Responses To Pandemic H1N1 Influenza Virus Infection In Pigs Vaccinated With A Conserved Hemagglutinin HA1 Peptide Adjuvanted With CAF®01 Or CDA/Αgalcermpeg". Vaccines 9 (7): 751. doi:10.3390/vaccines9070751. | ca |
dc.identifier.issn | 2076-393X | ca |
dc.identifier.uri | http://hdl.handle.net/20.500.12327/1549 | |
dc.description.abstract | This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF®01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF®01 or NG34 + CDA/αGCM. As controls, groups of animals (n = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund's adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 × 106 TCID50/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF®01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/αGCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/αGCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF®01 completely abolished virus from the lower respiratory tract. Similarly, higher IFNγ secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF®01 group as compared to the NG34 + CDA/αGCM. NG34-vaccinated pigs with adjuvanted CAF®01 or CDA/αGCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding. | ca |
dc.format.extent | 17 | ca |
dc.language.iso | eng | ca |
dc.publisher | MDPI | ca |
dc.relation.ispartof | Vaccines | ca |
dc.rights | Attribution 4.0 International | ca |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Immune Responses to Pandemic H1N1 Influenza Virus Infection in Pigs Vaccinated with a Conserved Hemagglutinin HA1 Peptide Adjuvanted with CAF®01 or CDA/αGalCerMPEG | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.description.version | info:eu-repo/semantics/publishedVersion | ca |
dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
dc.embargo.terms | cap | ca |
dc.relation.projectID | EC/H2020/730964/EU/European Vaccine Research and Development Infrastructure/TRANSVAC2 | ca |
dc.subject.udc | 619 | ca |
dc.identifier.doi | https://doi.org/10.3390/vaccines9070751 | ca |
dc.contributor.group | Sanitat Animal | ca |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
ARTICLES CIENTÍFICS [2.831]